Internet Archive Scholar

Weight and metabolic changes after switching from tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+DTG and TDF/FTC/efavirenz (EFV) to TDF/lamivudine (3TC)/DTG

Bronwyn Bosch, Godspower Akpomiemie, Nomathemba Chandiwana, Simiso Sokhela, Andrew Hill, Kaitlyn McCann, Ambar Qavi, Manya Mirchandani, Willem Daniel Francois Venter
2022

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (572.9 kB)
https://web.archive.org/web/20221217193850/https://watermark.silverchair.com/ciac949.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA0QwggNABgkqhkiG9w0BBwagggMxMIIDLQIBADCCAyYGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMdXEotI7VPCWIC2J8AgEQgIIC96tYjxHNzHz9RX_tRPsBVuisg3otFdVZtODJln_gmUgIrcFmiN671-RoZhyPuAJsxFCugq1WPvt5fIBVr5fej6L_S3pEcFE6J-6nNsKLFdVefTRyjTnGAsanWaXL4RrYc6PufGdcqr0_fi0HTaoOM2-N2p1j5cgyyDcAnYXZCDpJTll94wIUflxjK9ioSP6ul35f_1B7IiVNn3J4TQGO34alq63UtTjhM4jxHsDxpREd5uOGpJUZfTinKg1e0LYSt5O9aa28kO56hSzU8gJW3WSJ8FTwLzslELfRxiRMRvk5nukQ5RcxsNJaOkKdC1vqtVLTQKx9C0qP23S5u1xYPJZ156E5HAflO7tgRFDQ_ir_kMfwUmR1F9K_C-Vl-ltt6VBJa23CL_Vc5eo-Sh7p8gTQPP8pGZDNBBERLeR_5nPfqNUk__yFKbxp7ebe_JPJdn3-eRuVrpZ3EnSG9LyEBwun8Ho3IdOsuL4oOnLzDIhsIix3NL9BYkqG8rLpSgCt6d5b6q4f8144GOKC2SUlL235iNfhRfBKQflGhnozIy_IjRNw_2N2OVVfz-2-XnOKC8x9XQs1KHh47ILazJSAFh2hlFgmN-qSRO0v1eiUxZyLeXVBD-MCEdx0Ms40214vmRzWcD7wi40Q5RO5xH80I1ff4uys6pkSY6387Il9Be95tbxp0AF3QK-MChYHCYyH7LkRNRFvoHMVsYYrcf7HZUWpygcOnvn5FDlA1ONV_fc_cLYJxf7a960Aag056gEVI9A0nZ93bDOffEFrKbL5OOVK1o1YabHdL_qovwH8dQvmu6CM82iJ_ST-sLYRdl3OdAxYpx0LDdS6dByalLidB4rBLX78usVVfaG8H2bkJXv5rBtuM6mH58O61O_UR5zu13t9M6VsXUcOJ1FWJQ3dfR2GLC3LV2sqwM9V7sMwY_TOHrk__SfzX3JnJ9uO_CRdwMcnNilGpGoC3s79MmjDHJTPVg5xyBzX6NV5JlJadISWbOeKeAareg

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL. The file type is application/pdf.

Participants randomised to first-line tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+DTG or TDF/FTC/efavirenz (EFV) for 192 weeks were then switched to TDF/lamivudine (3TC)/DTG for 52 weeks. Participants switching either TAF/FTC+DTG or TDF/FTC/EFV to TDF/3TC/DTG showed statistically significant reductions in weight, low density lipoprotein, triglycerides, glucose and glycated haemoglobin.
doi:10.1093/cid/ciac949 pmid:36519389 fatcat:4y2vc4tnqnakjm3drp3pra5ptq
Citation

Bronwyn Bosch, Godspower Akpomiemie, Nomathemba Chandiwana, Simiso Sokhela, Andrew Hill, Kaitlyn McCann, Ambar Qavi, Manya Mirchandani, Willem Daniel Francois Venter. "Weight and metabolic changes after switching from tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+DTG and TDF/FTC/efavirenz (EFV) to TDF/lamivudine (3TC)/DTG." (2022)